GET DAILY SIGNALSCelldex Therapeutics (CLDX): Assessing the Path to the $64 Analyst Target
Key Takeaways
- The central stock price target of $64 is the arithmetic mean of roughly 13 current analyst price targets, rounded from about $63.70.
- Targets range widely, from $29 (Goldman Sachs) to $100 (Guggenheim), reflecting genuine disagreement over barzolvolimab's commercial potential and safety profile.
- With the latest verified price near $31.25, reaching $64 would require upside of roughly 105%, a very large move.
- The strongest support comes from Phase 3 EMBARQ-CSU results in chronic spontaneous urticaria (CSU) that met all primary and key secondary endpoints, with a BLA (Biologics License Application) filing guided for 2027.
- The biggest risks are a pre-revenue business model, ongoing safety debates, dilution risk, and execution risk ahead of commercialization.
- For more detail on the company's latest developments, visit Major News, Today's Price Move, the Forecast page, and Earnings.
- Explore Trending AI Robots for additional AI-driven market insights.
Analyst Price Targets and Consensus View
The $64 target is the average of the individual, named analyst targets reviewed, not an official published consensus. Estimates span a strikingly wide band of $29 to $100. At the cautious end, Goldman Sachs holds a Hold-equivalent rating with a $29 target, while Barclays sits at $53 and UBS at $45. At the bullish end, Guggenheim's $100 target stands well above the group, with Leerink Partners at $88, Cantor Fitzgerald and Wells Fargo at $72, and Canaccord Genuity and Stifel at $68.
Recent revisions have mostly been upward following the September 2026 Phase 3 readouts. Morgan Stanley raised its target to $61 from $57, Canaccord Genuity to $68 from $60, Stifel to $68 from $58, Leerink to $88 from $70, and H.C. Wainwright to $64 from $42. LifeSci Capital also moved to $64. The overall rating skew is clearly positive, but the spread between the low and high target—more than threefold—underscores that this is far from a settled debate. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent verified price of about $31.25, with a market capitalization near $2.45 billion, the required move to $64 is roughly 105%. By any standard, that is a very large move, far beyond routine price appreciation for an established company.
Celldex remains effectively pre-revenue, with trailing revenue under $200,000 and a GAAP net loss of roughly $75.6 million in the most recent quarter. The path to a higher valuation therefore depends almost entirely on barzolvolimab's clinical and commercial progress. Positive Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results showed strong efficacy in antihistamine-refractory and biologic-experienced patients, and management has guided to a BLA filing in 2027. The company reported approximately $650 million in cash as of the third quarter, which it expects to fund operations into 2028. From what I see, the cash position provides meaningful runway.
What Could Support a Move Toward the Target
- Positive pivotal data: Barzolvolimab met primary and all key secondary endpoints across two large Phase 3 trials, a rare outcome in immunology and the main driver of recent target increases.
- Differentiated mechanism: The drug targets the KIT receptor to deplete mast cells, positioning it for CSU patients who fail standard antihistamines and biologics.
- Pipeline optionality: Additional indications and CDX-622 broaden the franchise beyond CSU.
- Balance-sheet runway: Cash into 2028 reduces near-term financing pressure, though a commercial launch will still require substantial spending.
- Analyst momentum: Most firms have revised targets higher since the data, supporting sentiment.
What Could Prevent the Target From Being Reached
- Safety scrutiny: Analysts have debated barzolvolimab's adverse-event profile; H.C. Wainwright has called bear-case safety concerns overblown, but the debate could pressure the valuation until regulators weigh in.
- Execution risk: A successful BLA submission, approval, and commercial launch are all still ahead, with no guaranteed revenue.
- Dilution: Celldex filed an automatic mixed securities shelf, and future fundraising could dilute existing holders.
- Valuation compression: With no earnings and a negative P/E, the shares are valued on future promise alone, leaving them sensitive to sentiment shifts.
- Competition: The CSU and broader allergy landscape is competitive and evolving.
Technical Levels and Market Structure
The shares have traded between a 52-week low near $22.10 and a high near $45.14. After peaking earlier in the year, the stock pulled back and has consolidated near the $28–$31 zone, which now acts as a nearby support area, with $22 representing a deeper support level. The prior high near $45 stands out as the first major resistance level on any sustained advance, and the $30 level has psychological significance for traders. A move to $64 would require clearing both the $45 area and then new, uncharted territory well above the stock's historical range. I’m watching this closely for any breakouts from the current range.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though firms do not always disclose an exact period, and the wide $29–$100 range shows how differently analysts weigh the same facts. Key upcoming items include the 2027 BLA submission timeline, additional clinical data and regulatory interactions, any update on safety findings, and the pace of cash burn against the stated 2028 runway. Financing announcements and any changes to analyst ratings or targets will also matter.
Using Tickeron’s AI Daily Buy/Sell Signals for Monitoring
AI Daily Buy/Sell Signals from Tickeron uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. In my view, these signals can help investors tracking a volatile name like CLDX identify when market structure begins to change, providing an additional layer of insight alongside traditional research.
Final Assessment
Can CLDX reach $64? The average analyst price target of roughly $64 implies more than a 100% gain from current levels, a very large move that rests almost entirely on barzolvolimab's commercial future. Bullish analysts point to best-in-disease Phase 3 efficacy and a 2027 regulatory filing, while more cautious voices highlight a pre-revenue model, safety debates, and execution risk. The extraordinary spread between the $29 and $100 targets means the answer will ultimately be determined by regulatory and commercial milestones rather than by consensus math. Investors should watch the BLA timeline, safety updates, cash position, and analyst revisions for the clearest read on whether that path is becoming more or less credible.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLDX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Oscillator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLDX as a result. In 65 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 57 cases where CLDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of immunotherapy technologies for the treatment of cancer and other diseases
Industry Biotechnology
Advertisement